ExScientia Ltd

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ExScientia reports robust Q4 earnings, poised for precision medicine growth

ExScientia's Q4 2022 earnings call highlighted strong financial performance, key collaborations, and advancements in pipeline programs. The company's focus on AI-driven precision medicine and solid cash position bode well for future growth. Challenges in program management and cost control exist, but opportunities for innovation and partnerships are abundant.

ExScientia reports 15% revenue growth, poised for precision medicine leadership

ExScientia Ltd delivered strong financial performance with a 15% increase in quarterly revenue and a robust cash position, driven by successful product launches and cost-saving initiatives.
The company's focus on personalized medicine, innovative product development, and strategic financial management positions it well for future growth and market leadership.
While facing challenges in molecule differentiation and cost efficiency, ExScientia has opportunities to leverage biomarkers, advance clinical programs, and expand market presence.

ExScientia advances clinical trials and precision medicine with strong financials

ExScientia's Q2 2023 earnings call showcased progress in clinical trials, precision medicine, and AI integration, supported by a strong financial position.
The company's focus on innovation, cost efficiency, and strategic partnerships positions them well for future growth and advancements in drug discovery.
Challenges lie in managing milestone payments, operational complexities, and staying competitive through biologics investments and partnerships.
Opportunities abound in expanding collaborations, attracting industry interest, and unveiling advancements in biologics for pipeline growth from 2024 onwards.

ExScientia excels in Q3, poised for growth in precision medicine

ExScientia's Q3 performance reflects progress in oncology programs, financial strength, and a focus on precision drug design and partnerships.
The company's strengths lie in its robust cash position, innovative approach to drug design, and operational efficiency influenced by past projects.
Challenges include market adaptability, program prioritization, and maintaining competitiveness, while opportunities exist in advancing the pipeline and leveraging partnerships for growth.

ExScientia reports robust Q4 earnings, eyes growth through innovation

ExScientia's Q4 2023 earnings call showcases strong financial and operational performance.
The company's focus on innovation, partnerships, and efficiency drives growth.
Challenges include competition, innovation sustainability, and quality maintenance.
Opportunities lie in business development, automation, and efficient drug creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Recursion Pharmaceuticals

Blueprint Medicines

The past year provided a peek into the future of biotech and healthcare. Megafirms like Medtronic (NYSE: MDT ) led the way, partnering with tech giants such as Nvidia (NASDAQ: NVDA ), to develop AI-powered solutions to medical problems.

3 Biotech Stocks Using AI to Change Healthcare Forever

Exscientia has opened higher for three consecutive days. The company uses AI technology to speed drug discovery.

Why Shares of Exscientia Jumped on Wednesday

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first patient in its Phase 1/2 “ELUCIDATE” (GTAEXS617-001) study evaluating GTAEXS617 (‘617), Exscientia's precision-designed CDK7 inhibitor, for the treatment of advanced solid tumours. The clinical trial will evaluate the safety, efficacy and pharmacokinetics of ‘617 across multiple ascending doses in patients with advanced solid tumours including head and neck cancer, colorectal cancer, p.

First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) announced today that it is expanding its technology management structure to accelerate application of Exscientia's innovative technologies to catalyse instrumental change in the way drug candidates are being discovered, designed and developed for patients in need of innovative therapies. Over the last decade, Exscientia's AI-based drug design platform has successfully created five drugs currently in clinical trials and solved dozen.

Exscientia Announces Expansion of its Technology Leadership Team

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 11:20 a.m. PDT (7:20 p.m. BST). A live webcast of the fireside chat will be available on the Company's website, under the “Investors & Media” section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 3.

Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Predictive Oncology Inc

Schrodinger 

A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms.

3 Pharma Stocks That Will Boom Thanks to AI

Exscientia reported first-quarter earnings this week. The company has six programs derived from its AI-driven platform.

Why Shares of Exscientia Soared This Week

The company surprised on the upside with its latest set of quarterly figures. It topped analyst estimates for both revenue and net income.

Why Artificial Intelligence Stock Exscientia Leaped 6% Higher Today

Exscientia plc (NASDAQ:EXAI ) Q1 2023 Earnings Conference Call May 23, 2023 8:30 AM ET Company Participants Sara Sherman - Vice President of Investor Relations Andrew Hopkins - Chief Executive Officer Dave Hallett - Chief Scientific Officer Ben Taylor - Chief Financial Officer & Chief Strategy Officer Garry Pairaudeau - Chief Technology Officer Mike Krams - Chief Quantitative Medicine Officer Conference Call Participants Alec Stranahan - Bank of America Peter Lawson - Barclays Operator Hello, everyone. My name is Chris and I'll be your conference operator today.

Exscientia plc (EXAI) Q1 2023 Earnings Call Transcript

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST / 8:30 a.m. EDT. “With our sixth AI-designed compound reaching the clinical development stage plus two more in active IND/CTA-enabling studies, Exscientia's pipeline of wholly owned and partnered drug can.

Exscientia Business Update for First Quarter 2023

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced two abstracts for oral and poster presentation, as well as the closing keynote to be delivered at the Society for Laboratory Automation and Screening (SLAS) Europe Conference and Exhibition being held May 22-26, 2023, in Brussels, Belgium. These presentations highlight Exscientia's recent advancements in technology, including the development of computer-aided biology (CAB) approaches, encompassing design of experime.

Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe

Exscientia's AI-driven drug discovery platform has positioned the company at the forefront of precision medicine, revolutionizing the way new therapies are developed. Exscientia's pipeline has precision oncology programs, such as EXS74539 and EXS73565, along with the initiation of Phase 1/2 trials for A2A receptor antagonist EXS21546.

Exscientia's AI-Powered Drug Discovery Platform Is The Future Of Precision Medicine

OXFORD, England--(BUSINESS WIRE)--Professor Andrew Hopkins FRS FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been elected a Fellow of the Academy of Medical Sciences, one of the United Kingdom's four National Academies. He joins the Academy's 2023 cohort of 59 distinguished science leaders who have been recognised for their exceptional contributions to the advancement of biomedical and health science, cutting edge research discoveries and translating developments into.

Professor Andrew L. Hopkins elected Fellow of the Academy of Medical Sciences

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 24, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company's website at investors.exscientia.ai. Alternatively,.

Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma') plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule with potent dual 5-HT2A and 5-HT7 antagonist activity with broad potential in psychiatric disease. It is the third molecule created utilising Exscientia's AI-driven drug discovery platform under a collaboration with Sumitomo Pharma, r.

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

OXFORD, England--(BUSINESS WIRE)--Professor Andrew Hopkins DPhil LLD FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been elected a Fellow of the Royal Society, the world's oldest and most influential scientific society. Andrew is one of the UK's most eminent science and technology business leaders, pairing pharmaceutical research with the benefits of cutting-edge AI technology to design, discover and develop new precision medicines for people in need. He joins approxima.

Professor Andrew L. Hopkins elected Fellow of the Royal Society

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors. Prof. Michor is a professor of Computational Biology in the Department of Data Science at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and in the Department of Stem Cell and Regenerative Biology at Harvard University. The Board now comprises seven directors. “We ar.

Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced four presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14-19, 2023 in Orlando, FL. “We're excited to further validate Exscientia's end-to-end approach of integrating outstanding science with cutting-edge AI-driven precision medicine and translational research capabilities,” said Andrew Hopkins, D.Phil, founder and Chief Executive Officer of Exscientia.

Data Presented at AACR 2023 Highlights Exscientia's Clinical and Preclinical Development

Exscientia plc (NASDAQ:EXAI ) Q4 2022 Earnings Conference Call March 23, 2023 8:30 AM ET Company Participants Sara Sherman - VP-IR Andrew Hopkins - CEO Ben Taylor - CFO and Chief Strategy Officer Dave Hallett - Chief Scientific Officer Mike Krams - Chief Quantitative Medicine Officer Garry Pairaudeau - Chief Technology Officer Conference Call Participants Vikram Purohit - Morgan Stanley Peter Lawson - Barclays Operator Hello, everyone. My name is Chris and I will be your conference operator today.

Exscientia plc (EXAI) Q4 2022 Earnings Call Transcript

OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) Recent developments in the Company's pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below. Exscientia will host a conference call today, March 23, at 12:30 p.m. GMT / 8:30 a.m. EDT.

Exscientia Business and Financial Update for the Full Year 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company's website at investors.exscientia.

Exscientia to Report Full Year 2022 Financial Results on March 23, 2023

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that four abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023, at the Orange County Convention Center in Orlando, FL. These abstracts highlight the components of Exscientia's approach to precision discovery, design and personalised medicine as well as planned innovation in the clinic.

Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor. These compounds have been precision designed to improve the potential for patient benefit and solve complex design issues that may limit the probability of success of other compounds in development.

Exscientia Announces Expansion of its Precision Oncology Pipeline

OXFORD, England & BERLIN, Germany--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charité – Universitätsmedizin Berlin (Charité) to utilise Exscientia's AI-driven precision medicine platform in haematological cancers. Under the collaboration, Charité will evaluate the potential of Exscientia's precision medicine platform to select better treatments and improve outcomes for patients with haematological cancers.

Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform

AI has begun to make headways in the field of drug discovery and development. Exscientia offers investors direct exposure to this wave of innovation.

News for ExScientia Ltd Stock (EXAI)